TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on CHRS stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Michael Nedelcovych has given his Buy rating due to a combination of factors, including the alignment of Coherus Biosciences’ Q2 Loqtorzi sales with expectations and the company’s ambitious peak sales target for the product. The ongoing development of their pipeline assets, such as the anti-CCR8 mAb CHS-114 and the IL-27 antagonist casdozokitug, also contributes to a positive outlook, with significant data readouts expected in the first half of 2026.
Furthermore, Coherus Biosciences’ financial performance, including a Q2 net revenue that closely matched projections, supports the Buy rating. Despite a slightly higher non-GAAP net loss per share than forecasted, the company’s cash position is strong, with sufficient runway anticipated through 2026, allowing them to pursue strategic partnerships and continue their development programs.
According to TipRanks, Nedelcovych is an analyst with an average return of -17.7% and a 30.23% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Coherus Biosciences, and Bausch Health Companies.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.